Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 9, 2007, Pages 838-844

  Mok, Tony S K ^a,b   Ho, Simon ^a   Chan, Gong ^a   Ho, Wing Ming ^a   Wong, Herman ^a   Chan, Anthony T C ^a   Yeo, Winnie ^a   Yim, Anthony P C ^a   Chak, Karen ^a   Lee, Yolanda ^c   Lam, Kwok Chi ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NONE

Author keywords

Carcinoma; Combination; Docetaxel; Drug resistance; Drug therapy; Irinotecan; Non small cell lung

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GEFITINIB; GEMCITABINE; IRINOTECAN; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOLOGY; HUMAN; INCIDENCE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HONG KONG; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRODRUGS; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 34548445396     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181461976     Document Type: Article

References (34)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
2. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer. Results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367.
3. Bonomi P, Kim K, Faircloough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000;18:623-631.
4. Sandler A, Nemunaitis J, Dehnam C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122-130.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
6. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
7. Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003;21:3909-3917.
8. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomized multicentre trial. Lancet 2001;357:1478-1484.
9. Scagloiotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
10. Norton L, Simon R. Tumor size, sensitivity to therapy and design of treatment schedule. Cancer Treat Rep 1997;61:1307-1317.
11. Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986;46:3876-3885.
12. Liang Y, Leung KS, Mok TSK. A novel evolutionary drug scheduling model in cancer chemotherapy. IEEE Trans Inf Technol Biomed 2006;10:237-245.
13. Shepherd F, Cancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
14. Safran H, King T, Choy H, et al. P53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer 1996;78:1203-1210.
15. Lowe SW, Ruley HE, Jacks T, Housman DE. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
16. Nagao K, Fukuoka M, Fujita A, et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group [in Japanese]. Gan To Kagaku Ryoho 2000;27:413-421.
17. De Vore RF, Johnson DH, Crawfore J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol 1999;17:2710-2720.
18. Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 1999;22:399-402.
19. Mori K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1999;43:467-470.
20. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-341.
21. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 2007;18:317-323.
22. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506.
23. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
24. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switerland: World Health Organization, 1979. WHO offset pub. no. 48.
25. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994;30:635-642.
26. Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res 2000;9:129-137.
27. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-562.
28. Edelman MJ, Gandara DR, Lau D, et al. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Cancer 2001;92:146-152.
29. Edelman MJ, Clark JI, Chansky K, et al. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 2004;10:5022-5026.
30. Negoro S, Masuda N, Takada Y, et al. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 2003;88:335-341.
31. Fidias P, Dakhil SR, Lyss AP, et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer [abstract]. J Clin Oncol 2007;25(suppl):LBA7516.
32. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer . J Clin Oncol 1995;13:645-651.
33. Lilenbaum R, Socinski MA, Altorki NK, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006;24:4798-4800.
34. Socinski MA, Sandler AB, Miller LL, et al. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2001;19:1078-1087.